轉移性大腸直腸癌治療的新趨勢

New Trends in the Treatment of Metastatic Colorectal Cancer

10.6880/TJON.200912/SP_9.02

黃麟傑(Ling-Chieh Huang)

轉移性大腸結腸癌 ； 化學治療 ； 標靶治療 ； metastatic colorectal cancer ； chemotherapy ； targeted therapy

腫瘤護理雜誌

9卷S期（2009 / 12 / 01）

13 - 17

繁體中文

轉移性大腸直腸癌已成為一種可治癒的疾病。近年來由於在化學治療及其他相關輔助治療的進步，使得大腸直腸癌病患的治癒率顯著上升。其化學治療藥物的選擇扮演非常重要的角色，尤其是合併使用Biologics此類標靶治療藥物（例如Cetuximab或Bevacizumab），可以改善治療的反應率及增加轉移腫瘤切除率。

Metastatic colorectal cancer had become a potentially curable disease. Profound improvements in the outcomes of patients with metastatic colorectal cancer over the past years have been attributed to increased use of metastasectomy in selected patients and more effective chemotherapy. It is vital to choose the optimal conventional C/T combination for patients with initially unresectable liver tumors. The addition of Biologics (such as Cetuximab or Bevacizumab) to chemotherapy improves response rates and increases the proportion of metastatic tumor resection.